Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Official title: Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses.
Funded at Stanford University · NIH-11587807 · Data updated 2026-11-12
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | May 16, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $12,169,963 |
| NIH project number | 4U19AI171421-02 |
| Project ID | NIH-11587807 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with COVID-19 or other RNA virus infections who could benefit from outpatient antiviral therapy and participate in translational development efforts.
✕Less likely to help
This approach may not benefit individuals with conditions not driven by RNA viruses or those unable to take antiviral medications.
What this research studies
The project aims to create safe, effective antiviral combinations that can be taken outside the hospital setting. It involves three core areas: understanding how the drugs work at the molecular level, ensuring the work can be done safely with proper facilities, and translating findings into real-world treatments with industry partners. The effort includes multiple antiviral modalities such as small molecules, nucleic acids, and protein therapeutics, moving from discovery to IND-enabling steps. The goal is to bring these therapies closer to clinical use through milestone-based decisions and collaboration with experts across disciplines.
Why it matters
Potential benefit: If successful, patients could access effective outpatient treatments that reduce illness duration and prevent progression.
How similar studies have gone: Similar antiviral development programs have shown promise in preclinical stages, with translational paths guided by milestone-driven decisions.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Glenn, Jeffrey S — Stanford University
- Study coordinator: Glenn, Jeffrey S
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
-
How immune responses shape COVID-19's shift from outbreak to regular circulation
This project looks at how different antibody and mucosal immune responses after infection or vaccination affect COVID-19 spread in people living in a crowded urban community.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.